MSH2 Gene Lynch Syndrome (HNPCC) Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM–11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This comprehensive Next‑Generation Sequencing test analyzes the entire MSH2 gene for inherited mutations causing Lynch syndrome (hereditary nonpolyposis colorectal cancer type 1), providing lifetime cancer risk stratification and guiding personalized surveillance. The assay includes copy number variation (CNV) detection, achieving a variant detection limit down to 5% allele fraction.

Feature	Our Test (MSH2 NGS)	Closest Alternative
Method	NGS – high‑coverage sequencing + CNV analysis	Sanger sequencing (single‑gene) – no CNV detection
Detection Limit	Pathogenic variants down to 5% allele fraction	~15‑20% allele fraction; misses large deletions/duplications
Turnaround Time	3–4 Weeks	4–6 Weeks (with MLPA add‑on)
Clinical Utility	Gold‑standard Lynch syndrome diagnosis per NCCN/ESMO guidelines	Limited to point mutations; inferior risk stratification

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403) states: “An MSH2 mutation confers a significantly elevated lifetime risk for colorectal and endometrial cancers. This test provides actionable information for surveillance and prophylactic strategies. Always interpret results in the context of personal and family history through a formal genetic counseling session.”

Advisory: Medications and Precautions

Do not discontinue any prescribed medications without consulting your doctor. Inform your physician about all supplements and over‑the‑counter drugs before proceeding with testing.

Exclusion Criteria and Emergency Red Flags

Testing may be deferred if you have received an allogeneic blood transfusion within the last 2 weeks, or are actively undergoing bone marrow or stem cell transplant, as donor DNA may confound germline results. Acute haematological malignancies requiring urgent therapy should be discussed with the ordering physician. Seek immediate medical attention if you experience sudden severe abdominal pain, bright red rectal bleeding, or unexplained weight loss exceeding 5% of body weight in 6 months.

Patient FAQ & Clinical Guidance

1. What is the purpose of the MSH2 Genetic Test?

This test detects pathogenic variants in the MSH2 gene, confirming hereditary colorectal cancer and Lynch syndrome risk. It guides personalized cancer surveillance and preventive measures.

2. How is the sample collected and what preparation is needed?

A simple blood draw (peripheral whole blood) is performed by a certified phlebotomist at your home or in our facility. No special preparation is required. Ensure you are well‑hydrated for easier venous access.

3. How long do results take and will a doctor explain them?

Results are delivered in 3–4 weeks, followed by a complimentary tele‑consultation with a clinical geneticist to interpret findings and discuss next steps.

UAE Regulatory & Data Privacy Adherence

All genetic data is processed and stored in compliance with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
Federal Decree-Law No. 4 of 2016 on Medical Liability

This test is performed by DNA Labs UAE – DHA Facility License Number: 1143. Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.

Clinical & Logistical Metadata

Test Name	MSH2 Gene Lynch Syndrome (HNPCC) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (Standard Phlebotomy)
Methodology Used	Next-Generation Sequencing (NGS) with CNV Analysis
ICD-10-CM Code	Z15.09, Z80.0
LOINC Code	35095-5
DHA Facility License & Laboratory Address	License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE